Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « Titre (en) » - entrée « severe »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
seventh < severe < severely  Facettes :

List of bibliographic references indexed by severe

Number of relevant bibliographic references: 131.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000008 (2020) J. Prinz [Allemagne] ; Y. D'Hargues [Allemagne] ; P. Gödel [Allemagne] ; A. Shimabukuro-Vornhagen [Allemagne] ; M. Kochanek [Allemagne] ; B. Böll [Allemagne][CARs, CRS and neurotoxicity: severe complications after administration of immunotherapy : Essentials for intensivists].
000011 (2020) Binqing Fu ; Xiaoling Xu ; Haiming WeiWhy tocilizumab could be an effective treatment for severe COVID-19?
000015 (2020) Brian Lipworth [Royaume-Uni] ; Rory Chan [Royaume-Uni] ; Samuel Lipworth [Royaume-Uni] ; Chris Ruiwen Kuo [Royaume-Uni]Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection
000036 (2020) B P Hibler [États-Unis] ; A. Markova [États-Unis]Treatment of severe cutaneous adverse reaction with tocilizumab.
000067 (2020) Thomas Maldiney [France] ; Clémence Deschasse [France] ; Philip Bielefeld [France]Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves' Ophthalmopathy, a Report of Three Cases.
000083 (2020) Wen Zhang [République populaire de Chine] ; Yan Zhao [République populaire de Chine] ; Fengchun Zhang [République populaire de Chine] ; Qian Wang [République populaire de Chine] ; Taisheng Li [République populaire de Chine] ; Zhengyin Liu [République populaire de Chine] ; Jinglan Wang [République populaire de Chine] ; Yan Qin [République populaire de Chine] ; Xuan Zhang [République populaire de Chine] ; Xiaowei Yan [République populaire de Chine] ; Xiaofeng Zeng [République populaire de Chine] ; Shuyang Zhang [République populaire de Chine]The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China
000095 (2020) Chi Zhang [République populaire de Chine] ; Zhao Wu [République populaire de Chine] ; Jia-Wen Li [République populaire de Chine] ; Hong Zhao [République populaire de Chine] ; Gui-Qiang Wang [République populaire de Chine]The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality
000143 (2020) Eduardo Mysler [Argentine] ; Mario H. Cardiel [Mexique] ; Ricardo M. Xavier [Brésil] ; Alejandra L Pez ; Allan Ramos-Esquivel [Costa Rica]Subcutaneous Tocilizumab in Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Latin American Patients With Moderate to Severe Active Rheumatoid Arthritis: A Multicenter, Phase IIIb Study.
000150 (2020) Giovanna Garufi [Italie] ; Luisa Carbognin [Italie] ; Armando Orlandi [Italie] ; Giampaolo Tortora [Italie] ; Emilio Bria [Italie]Smoking Habit and Hospitalization for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Related Pneumonia: the unsolved paradox behind the evidence.
000155 (2020) Meng Xu ; Congcong Liu ; Lishuang Guo ; Sirui YangSevere sepsis caused by serious gastrointestinal infection in sJIA patients treated with IL-6 receptor antagonist: a case report
000156 (2020) Shuichiro Nakabo [Japon] ; Yuko Tsuji [Japon] ; Maiko Inagaki [Japon] ; Hideaki Tsuji [Japon] ; Toshiki Nakajima [Japon] ; Kosaku Murakami [Japon] ; Chikashi Terao [Japon] ; Motomu Hashimoto [Japon] ; Moritoshi Furu [Japon] ; Masao Tanaka [Japon] ; Hiromu Ito [Japon] ; Takao Fujii [Japon] ; Tsuneyo Mimori [Japon] ; Yasutomo Fujii [Japon]Severe joint deformity and Patient Global Assessment of Disease are associated with discrepancies between sonographic and clinical remission: A cross-sectional study of rheumatoid arthritis patients.
000185 (2020) Yuan-Yuan Wei [République populaire de Chine] ; Rui-Rui Wang [République populaire de Chine] ; Da-Wei Zhang [République populaire de Chine] ; You- Hui Tu [République populaire de Chine] ; Chang- Shan Chen [République populaire de Chine] ; Shuang Ji [République populaire de Chine] ; Chun-Xi Li [République populaire de Chine] ; Xiu-Yong Li [République populaire de Chine] ; Meng-Xi Zhou [République populaire de Chine] ; Wen- Sheng Cao [République populaire de Chine] ; Ming- Feng Han [République populaire de Chine] ; Guang-He Fei [République populaire de Chine]Risk factors for severe COVID-19: evidence from 167 hospitalized patients in Anhui, China
000209 (2020) Gonzalo De Luna [France] ; Anoosha Habibi [France] ; Jean François Deux [France] ; Martin Colard [France] ; Anne Laure Pham Hung D'Alexandry D'Orengiani [France] ; Frédéric Schlemmer [France] ; Nizar Joher [France] ; Christian Kassasseya [France] ; Jean Michel Pawlotsky [France] ; Clément Ourghanlian [France] ; Marc Michel [France] ; Armand Mekontso-Dessap [France] ; Pablo Bartolucci [France]Rapid and Severe Covid-19 Pneumonia with Severe Acute Chest Syndrome in a Sickle Cell Patient Successfully Treated with Tocilizumab.
000261 (2020) R. Tonelli [Italie] ; A. Iattoni [Italie] ; M. Girardis [Italie] ; L. De Pietri [Italie] ; E. Clini [Italie] ; C. Mussini [Italie]Never Give Up: Lesson learned from a severe COVID-19 patient
000350 (2020) Anna-Sophia Kattner ; Ernst Holler ; Barbara Holler ; Sebastian Klobuch ; Daniela Weber ; Danilo Martinovic ; Matthias Edinger ; Wolfgang Herr ; Daniel WolffIL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis
000377 (2020) Yan Zhang [République populaire de Chine] ; Ming Hu [République populaire de Chine] ; Dong Wei [République populaire de Chine] ; Hui Zhang [République populaire de Chine] ; Bao Chu [République populaire de Chine] ; Hao-Ming Xu [République populaire de Chine] ; Tao Wang [République populaire de Chine]From Severe Herpes Zoster to Rare Suid Herpesvirus Encephalitis: A New Twist of the Varicellovirus Genus Infection in Patients with Kidney Diseases
000387 (2020) Jeffrey P. Jacobs [États-Unis] ; Alfred H. Stammers [États-Unis] ; James St Louis [États-Unis] ; J W Awori Hayanga [États-Unis] ; Michael S. Firstenberg [États-Unis] ; Linda B. Mongero [États-Unis] ; Eric A. Tesdahl [États-Unis] ; Keshava Rajagopal [États-Unis] ; Faisal H. Cheema [États-Unis] ; Tom Coley [États-Unis] ; Vinay Badhwar [États-Unis] ; Anthony K. Sestokas [États-Unis] ; Marvin J. Slepian [États-Unis]Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in COVID-19: Experience with 32 patients.
000400 (2020) Muhammad Aziz [États-Unis] ; Rawish Fatima [États-Unis] ; Ragheb Assaly [États-Unis]Elevated Interleukin-6 and Severe COVID-19: A Meta-Analysis.
000419 (2020) Xiaoling Xu [République populaire de Chine] ; Mingfeng Han [République populaire de Chine] ; Tiantian Li [République populaire de Chine] ; Wei Sun [République populaire de Chine] ; Dongsheng Wang [République populaire de Chine] ; Binqing Fu [République populaire de Chine] ; Yonggang Zhou [République populaire de Chine] ; Xiaohu Zheng [République populaire de Chine] ; Yun Yang [République populaire de Chine] ; Xiuyong Li [République populaire de Chine] ; Xiaohua Zhang [République populaire de Chine] ; Aijun Pan [République populaire de Chine] ; Haiming Wei [République populaire de Chine]Effective treatment of severe COVID-19 patients with tocilizumab.
000424 (2020) Salah Ghabri [France] ; Aymeric Binard [France] ; Yves-Marie Pers [France] ; Franck Maunoury [France] ; J Jaime Caro [États-Unis]Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France.
000475 (2020) Farzaneh Dastan [Iran] ; Ali Saffaei [Iran] ; Seyed Mehdi Mortazavi [Iran] ; Hamidreza Jamaati [Iran] ; Nadia Adnani [Iran] ; Sasan Samiee Roudi [Iran] ; Arda Kiani [Iran] ; Atefeh Abedini [Iran] ; Seyed Mohammadreza Hashemian [Iran]Continues Renal Replacement Therapy (CRRT) With Disposable Hemoperfusion Cartridge: A Promising Option for Severe COVID-19

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i -k "severe" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i  \
                -Sk "severe" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Title.i
   |clé=    severe
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021